Text Size
Trial record 11 of 18 for:    Open Studies | "Muscular Atrophy, Spinal"
Previous Study | Return to List | Next Study

Motor Development and Orthoses in Spinal Muscular Atrophy (SMA)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by Arcispedale Santa Maria Nuova-IRCCS.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Arcispedale Santa Maria Nuova-IRCCS
ClinicalTrials.gov Identifier:
NCT00961103
First received: August 17, 2009
Last updated: NA
Last verified: August 2009
History: No changes posted
  Purpose

Spinal Muscular Atrophy (SMA) is neurodegenerative disease of anterior horn cells of spinal cord and represents the second more frequent pathology in childhood.

According to the age of onset and the maximum motor function the disorder is classified in 4 types. Patients with SMA II and SMA III often use orthoses to achieve postural and dynamic functions.

In this retrospective observational study the investigators describe the characteristics of sitting position, standing and walking correlated to type and time of orthoses used.


Condition
Spinal Muscular Atrophy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Assessment of Motor Development Related to Use of Orthoses in SMA II and III

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Arcispedale Santa Maria Nuova-IRCCS:

Primary Outcome Measures:
  • time and percentage of sitting, standing, walking achievement in SMA II and SMA III [ Time Frame: aug.2009- nov.2009 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • characteristics and percentage of orthoses for postural sitting control , standing and walking in SMA II and SMA III [ Time Frame: aug. 2009 - dec.2009 ] [ Designated as safety issue: No ]

Estimated Enrollment: 70
Study Start Date: September 2009
Estimated Study Completion Date: December 2009
Estimated Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
SMA II and SMA III
patients with SMA II and SMA III

Detailed Description:

We collect data from patients with SMA II and SMA III referred to UDGEE from jan. 1995 to dec. 2008.

We estimate to achieve informations about 50-70 patients.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients with SMA II and SMA III referred to UDGEE for rehabilitation consultation

Criteria

Inclusion Criteria:

  • Clinical and genetics diagnosis of SMA II and SMA III

Exclusion Criteria:

  • N/A
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00961103

Contacts
Contact: Manuela Lodesani, MD +390522296184 ext 5962 lodesani.manuela@asmn.re.it

Locations
Italy
UDGEE Hospital S.Maria Nuova Not yet recruiting
Reggio Emilia, RE, Italy, 42100
Contact: Manuela Lodesani, MD     +390522296184 ext 5962     lodesani.manuela@asmn.re.it    
Sub-Investigator: Mariacristina Filippi, PT            
Sponsors and Collaborators
Arcispedale Santa Maria Nuova-IRCCS
Investigators
Study Director: Adriano Ferrari, MD Hospital S.Maria Nuova Reggio Emilia Italy
  More Information

Publications:

Responsible Party: Lodesani Manuela, UDGEE Hospital S.Maria Nuova Reggi Emilia
ClinicalTrials.gov Identifier: NCT00961103     History of Changes
Other Study ID Numbers: UDGEE-SMA
Study First Received: August 17, 2009
Last Updated: August 17, 2009
Health Authority: Italy: The Italian Medicines Agency

Keywords provided by Arcispedale Santa Maria Nuova-IRCCS:
spinal muscular atrophy
motor development
orthoses

Additional relevant MeSH terms:
Muscular Atrophy, Spinal
Muscular Atrophy
Atrophy
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Pathological Conditions, Anatomical
 Signs and Symptoms
Spinal Cord Diseases
Central Nervous System Diseases
Motor Neuron Disease
Neurodegenerative Diseases
Neuromuscular Diseases

ClinicalTrials.gov processed this record on May 23, 2013